Table 1.
Clinicopathological characteristics of the patients included in the study.
| Clinicopathological Characteristics | n = 33 | % |
|---|---|---|
| Age (years)(median, range) | 65 (46–87) | |
| Sex | ||
| Male | 24 | 72.7 |
| Female | 9 | 27.3 |
| Smoking status | ||
| Smoker | 25 | 75.8 |
| Former smoker | 6 | 18.2 |
| Never smoker | 2 | 6.1 |
| Histological subtype | ||
| Adenocarcinoma | 24 | 72.7 |
| Squamous carcinoma | 4 | 12.1 |
| Large cell carcinoma | 1 | 3.0 |
| Poorly differentiated | 4 | 12.1 |
| Stage classification by TNM 1 standard | ||
| IIIA 2 | 2 | 6.1 |
| IIIB | 3 | 9.1 |
| IIIC | 1 | 3.0 |
| IVA | 16 | 48.5 |
| IVB | 11 | 33.3 |
| PD-L1 TPS 3 | ||
| <1% | 6 | 18.2 |
| 1-49% | 3 | 9.1 |
| ≥50% | 24 | 72.7 |
| First-line treatment | ||
| Pembrolizumab monotherapy | 24 | 72.7 |
| Pembrolizumab-Cisplatin-Pemetrexed | 9 | 27.3 |
1 TNM: tumor–node–metastasis staging. 2 IIIA: patients not candidates for surgery, radiation, or chemotherapy. 3 PD-L1 expression was assessed by tumor proportion scores (TPS) and reported by using a three cut-point system: TPS < 1%, TPS 1%–49%, and TPS ≥ 50%.